DE68904530D1 - Biologisch wirksames lipoprotein und seine verwendung. - Google Patents

Biologisch wirksames lipoprotein und seine verwendung.

Info

Publication number
DE68904530D1
DE68904530D1 DE8989850346T DE68904530T DE68904530D1 DE 68904530 D1 DE68904530 D1 DE 68904530D1 DE 8989850346 T DE8989850346 T DE 8989850346T DE 68904530 T DE68904530 T DE 68904530T DE 68904530 D1 DE68904530 D1 DE 68904530D1
Authority
DE
Germany
Prior art keywords
lipoprotein
pharmaceutical composition
patient
biologically effective
alveoli
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8989850346T
Other languages
English (en)
Other versions
DE68904530T2 (de
DE68904530T3 (de
Inventor
Tore Curstedt
Bjoern Loewenadler
Hans Joernvall
Bengt Robertsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swedish Orphan Biovitrum AB
Original Assignee
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20373667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68904530(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabi Pharmacia AB filed Critical Kabi Pharmacia AB
Application granted granted Critical
Publication of DE68904530D1 publication Critical patent/DE68904530D1/de
Publication of DE68904530T2 publication Critical patent/DE68904530T2/de
Publication of DE68904530T3 publication Critical patent/DE68904530T3/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE68904530T 1988-10-18 1989-10-11 Biologisch wirksames Lipoprotein und seine Verwendung. Expired - Fee Related DE68904530T3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19888803713A SE8803713D0 (sv) 1988-10-18 1988-10-18 Biologically active lipoprotein and its use

Publications (3)

Publication Number Publication Date
DE68904530D1 true DE68904530D1 (de) 1993-03-04
DE68904530T2 DE68904530T2 (de) 1993-07-29
DE68904530T3 DE68904530T3 (de) 1999-07-08

Family

ID=20373667

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68904530T Expired - Fee Related DE68904530T3 (de) 1988-10-18 1989-10-11 Biologisch wirksames Lipoprotein und seine Verwendung.

Country Status (8)

Country Link
US (2) US5223481A (de)
EP (1) EP0368823B2 (de)
JP (1) JP2963923B2 (de)
AT (1) ATE84799T1 (de)
AU (1) AU623180B2 (de)
CA (1) CA2000893C (de)
DE (1) DE68904530T3 (de)
SE (1) SE8803713D0 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0329794B1 (de) * 1987-09-01 1994-03-30 Teijin Limited Verfahren zum testen einer wirksamen substanz die sich auf der oberfläche menschlicher lungen befindet
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
DK0482097T3 (da) * 1989-07-11 2001-09-17 Genentech Inc Tensidpræparater og fremgangsmåder
CA2063273C (en) * 1989-07-11 2002-09-24 Bradley J. Benson Surfactant compositions and methods
EP0458167B1 (de) * 1990-05-21 1997-04-23 Abbott Laboratories Fettsäure-Oberflächenaktives-Lungenprotein Konjate
US5258496A (en) * 1990-07-10 1993-11-02 Scios Nova Inc. Isolation and purification of lung surfactant protein
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
JP3961029B2 (ja) * 1992-06-24 2007-08-15 博 木戸 インフルエンザウィルス感染防止剤
EP0733645B1 (de) * 1993-12-08 2003-03-19 Mitsubishi Pharma Corporation Neuartiges sythetisches Peptil, diese enthaltende Zusammensetzung und Arznei-Zusammensetzung und Arznei gegen das Atemnotsyndrom
DE4418936A1 (de) * 1994-05-31 1996-02-08 Byk Gulden Lomberg Chem Fab Polypeptid
FR2739860B1 (fr) * 1995-10-17 1998-01-02 Coletica Complexes amphiphiles, procede pour leur preparation et compositions en renfermant
WO1997043313A1 (en) * 1996-05-15 1997-11-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for separating and analyzing hydrophobic proteins using thin layer chromatography
US6476191B1 (en) 1999-02-05 2002-11-05 Mixture Sciences, Inc. Volatilizable solid phase supports for compound synthesis
IT1308180B1 (it) 1999-02-12 2001-12-07 Chiesi Farma Spa Peptidi sintetici aventi la capacita' di diminuire la tensionesuperficiale e loro impiego nella preparazione di un surfattante
EP1216052A1 (de) 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Kombination eines c1-inh und eines lungensurfactant zur behandlung von respirationstörungen
AU2002338882B2 (en) 2001-10-11 2008-04-03 Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. Novel use of pulmonary surfactant
WO2006013183A1 (en) 2004-08-06 2006-02-09 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
US7582312B2 (en) 2004-11-15 2009-09-01 Discovery Laboratories, Inc. Methods to produce lung surfactant formulations via lyophilization and formulations and uses thereof
US7464012B2 (en) * 2004-12-10 2008-12-09 L'air Liquide, Societe Anonyme A Directoire Et Conseil De Surveillance Pour L'etude Et L'exploitation Des Procedes Georges Claude Simplified process simulator
EP2298349A1 (de) 2005-01-06 2011-03-23 Discovery Laboratories, Inc. Dosierungsschema für Tenside zur Behandlung oder Verhinderung von bronchopulmonären Dysplasien
JP2007309695A (ja) * 2006-05-16 2007-11-29 Univ Of Tokyo 質量分析のための脂質修飾ペプチドの抽出方法
CA2663795A1 (en) * 2006-09-19 2008-03-27 Discovery Laboratories, Inc. Pulmonary surfactant formulations and methods for promoting mucus clearance
US7951781B2 (en) 2006-11-02 2011-05-31 University Of Iowa Research Foundation Methods and compositions related to PLUNC surfactant polypeptides
US20100284969A1 (en) * 2007-06-05 2010-11-11 Frank Guarnieri Methods and Compositions for Delivery of Medicaments to the Lungs
US9289388B2 (en) 2008-12-10 2016-03-22 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
WO2013188016A2 (en) 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4234475A (en) * 1975-08-15 1980-11-18 The Gillette Company Reacting protein with organic acid
DE2925942A1 (de) * 1979-06-27 1981-01-22 Bayer Ag Disazokupferkomplex-reaktivfarbstoffe
US4406833A (en) * 1982-06-04 1983-09-27 Fats And Proteins Research Foundation, Inc. Surfactants derived from fatty acid esters and proteinaceous material
US4659805A (en) * 1984-12-11 1987-04-21 California Biotechnology, Inc. Recombinant alveolar surfactant protein
US4933280A (en) * 1984-12-11 1990-06-12 California Biotechnology Inc. Recombinant DNA sequence encoding Alveolar Surfactant Protein
US4882422A (en) * 1985-10-24 1989-11-21 Genetics Institute, Inc. Pulmonary surfactant proteins
US4918161A (en) * 1985-09-26 1990-04-17 Genetics Institute, Inc. Low molecular weight pulmonary surfactant proteins
WO1987006943A1 (en) * 1986-05-06 1987-11-19 Children's Hospital Medical Center Pulmonary hydrophobic surfactant-associated protein of 6,000 daltons molecular weight and multimers thereof
US5013720A (en) * 1986-05-06 1991-05-07 Abbott Laboratories SAP-6-Val proteins and methods
EP0290516A4 (de) * 1986-10-24 1989-11-14 Jeffrey A Whitsett Proteine, die mit oberflächenwirksamen hydrophoben lungenwirkstoffen verbunden sind.
JPH01501282A (ja) * 1986-12-08 1989-05-11 ホイツトセツト，ジエフリー　エイ． 肺胞疎水性界面活性物質関連タンパク質
IT1203873B (it) * 1987-04-08 1989-02-23 Chiesi Farma Spa Composizioni farmaceutiche che lo surfattante polmonare naturale, contengono. metodo di preparazione e
WO1989000167A1 (en) * 1987-07-01 1989-01-12 Kabigen Ab Proteins and protein compositions and their use
US4861756A (en) * 1988-03-08 1989-08-29 Merrell Dow Pharmaceuticals Inc. Synthetic pulmonary surfactant
SE8803713D0 (sv) * 1988-10-18 1988-10-18 Kabigen Ab Biologically active lipoprotein and its use
US4993280A (en) * 1989-07-17 1991-02-19 Motorola, Inc. Rotational control assembly

Also Published As

Publication number Publication date
AU623180B2 (en) 1992-05-07
US5223481A (en) 1993-06-29
CA2000893C (en) 2000-08-08
ATE84799T1 (de) 1993-02-15
EP0368823A2 (de) 1990-05-16
US5455227A (en) 1995-10-03
DE68904530T2 (de) 1993-07-29
EP0368823A3 (en) 1990-05-23
DE68904530T3 (de) 1999-07-08
JP2963923B2 (ja) 1999-10-18
SE8803713A (de) 1988-10-18
EP0368823B2 (de) 1998-12-23
EP0368823B1 (de) 1993-01-20
AU4299689A (en) 1990-04-26
JPH02145599A (ja) 1990-06-05
SE8803713D0 (sv) 1988-10-18
CA2000893A1 (en) 1990-04-18

Similar Documents

Publication Publication Date Title
DE68904530D1 (de) Biologisch wirksames lipoprotein und seine verwendung.
DK1201241T3 (da) Sammensætninger indeholdende capsaicin eller capsaicinanaloge og et bedøvelsesmiddel
ATE55908T1 (de) Grenzflaechenaktives mittel und dieses enthaltende arzneimittel zur verwendung bei der behandlung des atemnotsyndroms.
EP0210189A4 (de) Rekombinantes alveolares oberflächenaktives protein.
ATE344043T1 (de) Stabiler hypoxie-induzierbarer faktor-1 alpha und verfahren zur verwendung
FR2695317B1 (fr) Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.
NO954691D0 (no) Reduksjon av liposom-indusert ugunstige fysiologiske reaksjoner
DE69122364D1 (de) Verwendung von (S)-Isofluran und (S)-Desfluran zur Anästhesie sowie entsprechende Arzneimittelzubereitungen
DE68912589T2 (de) Mittel zur verbesserung des fettabbaus und verfahren zur verwendung.
DE69333412D1 (de) Übergangszustand-analoga des kokains, ihre verwendung zur herstellung von kataltischen antikörpern gegen kokain und verwendung derselben in diagnose und therapie
ATE88633T1 (de) Verwendung von bestimmten calcium-citrate-malaten zur herstellung einer pharmazeutischen zubereitung fuer die behandlung von osteoporose.
ATE183651T1 (de) Verwendung von wachstumsfaktor igf-ii zur beahandlung von gastrointestinalen störungen
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
BE894185A (fr) Formulations pharmaceutiques comprenant de l'insuline humaine et du c-peptide humain
IL90975A0 (en) Non-glycosylated,recombining human il 2 in reduced form,the process for obtaining it and its use as a medicament
FI915654A (fi) Somatotropiner med alterneringar i alfahelixregionen 1 och kombinationer med andra mutationer.
DE69919969D1 (de) Humanes Wachstumshormon zur Stimulierung der Hämatopoese und der Immunrekonstitution nach hämatopoetischer Stammzelltransplantation beim Menschen
ES2092969A1 (es) Surfactante pulmonar natural de origen porcino.
Code et al. Expansion of stimulus-evoked metabolic activity in monkey somatosensory cortex after peripheral denervation
GB2198351B (en) Improvements in or relating to the use of epidermal growth factor for enhancing the uptake of iron in vivo.
ATE40795T1 (de) Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
DK0434989T3 (da) Fremgangsmåde til forbedring af ventilationen under søvn og til behandling af søvnrelaterede ventilationsabnormaliteter
Duncan Effect of anesthesia and surgery on the immune system.
Brouqui et al. Treatment of osteo-arthritis with ofloxacin. Preliminary report.
DE19957898A1 (de) Neue Verwendung von Lungensurfactant

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA & UPJOHN AB, STOCKHOLM, SE

8366 Restricted maintained after opposition proceedings
8327 Change in the person/name/address of the patent owner

Owner name: BIOVITRUM AB, STOCKHOLM, SE

8339 Ceased/non-payment of the annual fee